ABPI and UK Government bring forward VPAG pricing review
The UK Government and the Association of the British Pharmaceutical Industry (ABPI) have agreed to accelerate the planned review of the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG).
Originally scheduled for autumn 2025, the review will now conclude by June 2025. This decision follows concerns from pharmaceutical businesses about the scheme's impact on investment in the UK life sciences sector. The review aims to ensure that VPAG continues to support both the NHS's affordability and access to innovative medicines, while maintaining the UK's competitiveness in the global pharmaceutical market.
For more details, you can read the full announcement from the ABPI.